KDR and Alzheimer disease: To evaluate the contribution of abnormal angiogenesis to the progression of the disease, we treated an AD mouse model with sorafenib, a drug that inhibits the intracellular activity of several angiogenic kinases (VEGFR, PDGFR, and RAF) in endothelial cells.